Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including ...

J&J will now pick up almost the full tab for the phase 3 trial, and, in return, Nanobiotix will see the potential milestone ...

An 85-year-old who credits the Lingen Davies Cancer Centre with saving his life is preparing for a final trip to his beloved ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Dr Toral Vaidya, a New York City based board certified dermatologist, recently shared signs and symptoms of skin cancer she ...

Dr Toral Vaidya, a dermatologist based in New York City, has shared the different types of skin cancer there are and the ...

High sugar-sweetened beverage intake was associated with increased oral cavity cancer in women – regardless of smoking or ...

Sitaben Purohit, the owner of the city's renowned Shree Thaker Bhojanalay, has undergone 60 surgeries over the past 25 years for oral canc.

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...